BriaPro sub of BriaCell reports $420K net loss, going concern uncertainty

BriaCell Therapeutics Corp.

BriaPro incurred net loss of $420,287 for year ended July 31, 2024; accumulated deficit $440,209 since incorporation in May 2023.
Total assets $199,797; current liabilities $455,650; shareholders' deficit $405,694; cash balance $1.
Auditor's report includes material uncertainty paragraph about going concern; company is pre-clinical with no commercial operations.
Intangible assets (patents) of $199,796 acquired from BriaCell via spinout arrangement on August 31, 2023.
BriaCell beneficially owns 2/3 of BriaPro's outstanding common shares (31,963,452 of 47,945,178 shares).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.